Progression free survival (PFS) of 74% at 16 months compares favourably to standard of care PFS of 50% at 11.5 months 1 Strong PFS consistent across key subgroups Reaffirms selection of iSCIB1+ and target HLA population for late-stage development Early overall survival (OS) data, most advanced for SCIB1, showing a 14% improvement at 26 months over SoC1 In advanced planning for registrational trials with positive scientific advice from regulators To hold late-breaking oral presentation on SCOPE trial at ESMO ...

Scancell Holdings plc Scancell holds oral presentation of positive Phase 2 data on Immunobody® iSCIB1+ in late-stage melanoma at SITC 2025 Data from SCOPE trial show a potential new benchmark in efficacy, durability, immune responses and safety Progression-free survival (PFS) for iSCIB1+ in target population at 11 months is 78%, compared with historic 12 months PFS of 46% with doublet checkpoint therapy of ipilimumab and nivolumab Development plans for iSCIB1+ accelerated including regulatory and partner ...

NOTTINGHAM, United Kingdom, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Scancell Holdings plc (AIM: SCLP), the developer of ImmunoBody® and Moditope® active immunotherapies to treat cancer, today announces a business update and provides its final audited financial results for the year ended 30 April 2025. Key highlights (including post-period) DNA ImmunoBody® SCIB1/iSCIB1+ (SCOPE trial) Positive data reported from Phase 2 SCOPE trial shows iSCIB1+ in combination with checkpoint inhibitors has the potential to set th ...

NOTTINGHAM, United Kingdom, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Scancell Holdings plc (AIM: SCLP), the developer of ImmunoBody® and Moditope® active immunotherapies to treat cancer, today announces a business update and provides its final audited financial results for the year ended 30 April 2025. Key highlights (including post-period) DNA ImmunoBody® SCIB1/iSCIB1+ (SCOPE trial) Positive data reported from Phase 2 SCOPE trial shows iSCIB1+ in combination with checkpoint inhibitors has the potential to set th ...

SCOPE trial of SCIB1/iSCIB1+ plus standard of care shows excellent results encompassing efficacy, durability, immune responses and safety Overall response rate for iSCIB1+ was 69% for target HLA type patients, representing 80% of total patients - greatly exceeding the 48-50% for standard of care 12-month progression-free survival also markedly improved, with a 20% increase over standard of care iSCIB1+ Immunobody® selected for future development; planning for registrational Phase 2b/3 global study accelerat ...